Professional background

I completed my clinical training at St Bartholomew’s and University College London Hospitals. I completed a PhD at the Institute of Cancer Research and the Royal Marsden Hospital which looked at the genes that predispose patients to prostate cancer.

I now specialise in the treatment of soft tissue and bone sarcomas using chemotherapy and radiotherapy. I have a strong interest in clinical research and am currently in the process of developing a number of new local and national research projects in sarcoma. I teach and lecture regularly in the management of sarcomas.

Research interests

Breast sarcoma

Soft tissue and bone sarcomas

Gynaecological sarcomas

Languages spoken



Ahmed M, Goh C, Saunders E, Cieza-Borrella C; PRACTICAL consortium, Kote-Jarai Z, Schumacher FR, Eeles R. Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate Cancer Prostatic Dis. 2020 Jun;23(2):333-342. doi: 10.1038/s41391-019-0181-y. Epub 2019 Nov 27. PMID: 31776447; PMCID: PMC7237354

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M et al. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature communications. 2018;9(1):2256.

​​​​​​​Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature genetics. 2018;50(7):928-36.

​​​​​​​​​​​​​​Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M,  Zamora JButler AWhitaker HKote-Jarai ZAlexandrov LBVan Loo P,Massie CEDentro SWarren AYVerrill CBerney DMDennis NMerson SHawkins SHowat WLu YJLambert AKay JKremeyer BKaraszi KLuxton HCamacho NMarsden LEdwards SMatthews L Bo VLeongamornlert DMcLaren S Ng AYu YZhang HDadaev TThomas SEaston DFAhmed M et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature genetics. 2018;50(5):682-92.

​​​​​​​​​​​​​​Ahmed M, Eeles, R. Germline genetic profiling in prostate cancer: latest developments and potential Clinical applications. Future Science OA, March 2016 ,Vol. 2, No. 1 , DOI 10.4155/fso.15.87

​​​​​​​​​​​​​​Ahmed M, Dorling L, et al. Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. British Journal of Cancer, 2016 May 10;114(10):1165-74.

​​​​​​​​​​​​​​Ahmed M et al. Medical Treatment of Urological Malignancies. Biology of Androgen Dependence and Castration Resistance.   European Association of Urology, (

​​​​​​​​​​​​​Eleanor Jones, Christos Mikropoulos Ahmed M. The Future of Immunology in the Treatment of Lung Cancer. Future Medicine, April 2015 ,Vol. 4, No. 2, Pages 57-7

​​​​​​​​​​​​​​Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, et al.  A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.  Nature Genetics. 2014 Oct;46(10):1103-9.

​​​​​​​​​​​​​​Woolf D, Ahmed M, Plowman N. Primary Lymphoma of the Ocular Adnexa (Orbital Lymphoma) and Primary Intraocular Lymphoma. Clinical Oncology, Volume 24, Issue 5, June 2012, P 339-344.

​​​​​​​​​​​​​​​​​​​​​M Ahmed, A. KosgallanaD. SoonD. O’DonovanA. Chaudhuri. Respiratory muscle weakness in a patient with quiescent Crohn’s disease and pneumonia. QJM, 2008, Vol 101, Issue 3, P 245-247.